<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01018485</url>
  </required_header>
  <id_info>
    <org_study_id>HREC 2008.022</org_study_id>
    <nct_id>NCT01018485</nct_id>
  </id_info>
  <brief_title>The Efficacy of Botulinum Toxin in Disabling Multiple Sclerosis (MS) Tremor</brief_title>
  <official_title>Double-Blind, Randomized, Controlled, Cross-over Comparison of Efficacy and Safety of Botulinum Toxin Type A in the Targeted Treatment of Disabling Tremor in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Melbourne Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastern Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Melbourne Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The incidence of tremor in Multiple Sclerosis (MS) has been estimated to affect up to 2/3rds
      of patients. Over half of the tremors involve the upper limb and frequently lead to further
      disability. Medical treatment of MS tremor is generally unrewarding, although carbamazepine,
      clonazepam, glutethimide, hyoscine, isoniazid, ondansetron, primidone, and
      tetrahydrocannabinol have been reported to have some beneficial effect but published evidence
      of effectiveness is very limited. The investigators' experience to date suggests that many of
      the upper limb tremors may potentially be responsive to Botulinum toxin injection therapy.

      Aims:

      1. The investigators aim to determine the efficacy of commonly used doses of BOTOX on the
      patients with symptomatic unilateral or bilateral arm tremor due to MS; and any side effects
      associated with this treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A decrease in tremor</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The safety profile of Botulinum Toxin in MS patients</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Tremor</condition>
  <arm_group>
    <arm_group_label>Botulinum Toxin First Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinded and Randomized injection of 20 upper limbs with Botulinum Toxin Type A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botulinum Toxin Second Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 patients will receive Placebo as first dose and Botulinum Toxin as second dose injection 3 months after initiation of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum Toxin Type A</intervention_name>
    <description>Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.</description>
    <arm_group_label>Botulinum Toxin First Dose</arm_group_label>
    <arm_group_label>Botulinum Toxin Second Dose</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Relapsing-remitting MS or secondary progressive MS according to the Mc Donald criteria

          -  Age 18-80 years of age

          -  Competent to understand and sign informed consent

          -  Presence of symptomatic head and/or limb tremor

        Exclusion Criteria:

          -  Treatment with botulinum toxin type A of any brand within the 4 months prior to
             enrollment

          -  A known contraindication to Botox injection

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Evans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Melbourne Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Melbourne Health</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 19, 2009</study_first_submitted>
  <study_first_submitted_qc>November 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 23, 2009</study_first_posted>
  <last_update_submitted>May 8, 2015</last_update_submitted>
  <last_update_submitted_qc>May 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <name_title>Dr Andrew Evans</name_title>
    <organization>Royal Melbourne Hospital, Neurologist</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Tremor</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

